GlassScriptPhysician profile
Lloyd D Lorenz
NPI 1255418125
$5,476.95
in general payments reported to CMS, 2019-2025
42 companies · $98.81 in 2025
The $98.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $1,201 · 2021: $2,281 · 2022: $104 · 2023: $314 · 2024: $221 · 2025: $98.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $517.61 | 2019-2021 | |
| Glaxosmithkline, LLC. | $502.28 | 2019-2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $450.45 | 2019-2021 | |
| Abbvie INC. | $427.05 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $375.08 | 2019-2021 | |
| Abbott Laboratories | $366.90 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $314.96 | 2019-2024 | |
| Lilly USA, LLC | $279.59 | 2019-2021 | |
| Amarin Pharma, INC. | $223.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.91 | 2019-2021 | |
| Astellas Pharma US INC | $191.72 | 2019-2021 | |
| Allergan, INC. | $175.18 | 2020 | |
| Exact Sciences Corporation | $163.06 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $141.88 | 2019-2021 | |
| Corcept Therapeutics | $104.92 | 2021-2024 | Korlym |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Lorenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.